Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

    ... under treatment with the anti-complement antibody eculizumab who developed pancytopenia , requiring blood ...

    Research Article last updated 01/08/2014 - 9:53am.

  2. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab.

    ... an increased rate of premature labor and fetal loss. Eculizumab , a humanized monoclonal antibody directed against the terminal ... has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

    ... 27 years at pregnancy. None of these women had received eculizumab during their pregnancy. Maternal complications, consisting ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Safety and Effect of GL-ONC1 Administered IV With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

    ... product, GL-ONC1, alone or in combination with eculizumab . This study aims to find the highest dose of GL-ONC1 that can be given alone, or with eculizumab, without causing unacceptable side effects. GL-ONC1 is considered ...

    Clinical Trial last updated 04/28/2016 - 1:57pm.

  5. A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients

    ... measures, four patients with classic PNH received eculizumab whereas four patients with PNH/BMD underwent hematopoietic stem ...

    Research Article last updated 05/02/2017 - 10:42am.

  6. Interviews with the Experts: Side Effects of PNH Treatment

    Although eculizumab (Soliris®) is known to be effective in treating PNH, it has ... The most frequently reported side effects of eculizumab in the PNH randomized trial were: headache, nasopharyngitis, back ... adverse reactions occurred among 4 (9%) patients receiving eculizumab and 9 (21%) patients receiving placebo (inactive ...

    Interview last updated 08/31/2016 - 8:37am.

  7. Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria

    ...

    Research Article last updated 04/29/2016 - 10:20am.

  8. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab

    ... 26, 2017 Eculizumab is indicated for the therapy of patients with symptomatic ... to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two ...

    Research Article last updated 02/03/2017 - 11:21am.

  9. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide

    ... . Patients with PNH prior to the availability of eculizumab had a median survival of between 10 and 22 years, with ...

    Research Article last updated 03/22/2017 - 2:43pm.

  10. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria

    ... The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients ... reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk ...

    Research Article last updated 07/30/2012 - 2:23pm.